Related Experiment Videos
Guidelines for the treatment of mild hypertension
W H Birkenhäger1, P W de Leeuw
1Department of Medicine, Zuiderziekenhuis, Rotterdam.
Insights
Early treatment for mild hypertension, defined by diastolic blood pressure between 90-104 mm Hg, offers benefits. This review examines randomized trials to guide early intervention strategies for mild diastolic hypertension.
Area of Science:
- Cardiology
- Public Health
Background:
- Mild hypertension is characterized by persistent diastolic blood pressure between 90-104 mm Hg.
- Systolic blood pressure is an independent cardiovascular risk factor.
Purpose of the Study:
- To derive practical guidelines for the early treatment of uncomplicated mild hypertension.
- To evaluate the benefits and risks associated with early intervention in mild diastolic hypertension.
Main Methods:
- Review of randomized placebo-controlled blind trials.
- Analysis of data from the USPHS, ANBPS, and MRC trials.
- Focus on uncomplicated mild hypertension, primarily mild diastolic hypertension.
Main Results:
- Evidence from major trials supports the benefits of early treatment for mild hypertension.
- Risk-benefit analysis guides practical treatment recommendations.
- Guidelines are derived from placebo-controlled trial data.
Conclusions:
- Early treatment is beneficial for mild hypertension, particularly mild diastolic hypertension.
- Guidelines should consider both the advantages and potential risks of early intervention.
- Randomized trials provide a robust evidence base for clinical decision-making.
Abstract:
Mild hypertension is defined as a state in which diastolic blood pressures ranging from 90 to 104 mm Hg are persistently observed. Systolic blood pressure is increasingly being recognised as a risk factor in its own right. Strictly speaking, the lessons learnt from the prospective trials in mild hypertension apply mainly to the stratum of mild diastolic hypertension. In this review, randomised placebo-controlled blind trials in uncomplicated mild hypertension (USPHS, ANBPS, MRC trials) will serve as the main data base from which to derive practical guidelines, in terms of benefits and risks, of early treatment.